Gut Registry

entity · release 2026-09-20

Limosilactobacillus reuteri ATCC PTA 6475

Structured fields rendered from the release dataset. Unknown values retain a reason; price is outside GIS.

Containing labels1
Evidence amount0.92
Direction balanceThe direction of the study results has not been extracted.

Matched PubMed records

8 records (retracted records excluded; 0 retracted records match the query separately). PubMed query

Matched records include trials of multi-ingredient products; this is not a count of trials of this entity alone.

  1. 2024 · The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.
  2. 2024 · Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial.
  3. 2024 · Precision microbial intervention improves social behavior but not autism severity: A pilot double-blind randomized placebo-controlled trial.
  4. 2022 · One-year supplementation with Lactobacillus reuteri ATCC PTA 6475 counteracts a degradation of gut microbiota in older women with low bone mineral density.
  5. 2022 · Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
  6. 2019 · Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
  7. 2018 · Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial.
  8. 2014 · Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.

ClinicalTrials.gov

0 interventional studies. ClinicalTrials.gov query

This species has 22 tracked designations; this one appears on 1 labels (median 4).

Species and related strains

Limosilactobacillus reuteri

Axis 1 · inverted

Containing label versions

Showing 1 of 1 rows, ordered by Gut Index Score descending, then DSLD label ID. Download full CSV · Download full JSON.

BrandProductDSLDGut Index ScoreStrain namedPer-organism quantityPotency basisVersions
BioGaiaGastrus311007Not available in this release.trueundefined: light snapshotnot stated1

Axis 2

Studiedness

Evidence amount
0.92
Direction balance
The direction of the study results has not been extracted.
PMID records loaded
8
Records after title/year deduplication
8

Axis 3

Measurement integrity

Not a measurement product, so this axis does not apply.

Axis 4

Reddit mention panel

0 observed mentions; no aggregate panel matched this entity.

Elsewhere in this release

Related pages

Findings computed over the whole corpus: Strain naming census · Label designation changes · Strain dose match · Stability literature gaps

Tools: DSLD product check · Unit value calculator

Citation

Cite this page

Ivitskiy, I. (2026). Limosilactobacillus reuteri ATCC PTA 6475. Gut Registry, release 2026-09-20. Elanvale Ltd. https://gutregistry.com/s/limosilactobacillus-reuteri-atcc-pta-6475/

The underlying tables are published under CC BY 4.0: this page as CSV · as JSON · full release and data dictionary. Cell-level provenance names the source record and its observation date.

Citable atoms

Release claims

  1. Limosilactobacillus reuteri ATCC PTA 6475 appears on 1 of 13,330 labels in the NIH DSLD snapshot (Sep 2026), from 1 brands; tied with 227 designations by distinct label count.

    1 / 13330 observed label versions · NIH DSLD snapshot Sep 2026 · entity.prevalence · checked 2026-09-20T00:00:00Z · snapshot b7633f732437

  2. 0 of 1 containing labels in the NIH DSLD snapshot (Sep 2026) print a quantity for Limosilactobacillus reuteri ATCC PTA 6475 (0.0%); 1 light records have quantities unavailable.

    0 / 1 containing labels · NIH DSLD snapshot Sep 2026 · entity.quantity · checked 2026-09-20T00:00:00Z · snapshot b7633f732437

  3. 8 PubMed records indexed as human randomized controlled trials match the published query (as of 2026-09-15). 8 records (retracted records excluded; 0 retracted records match the query separately).

    Published PubMed query

    8 / 8 loaded PMID records · NIH DSLD snapshot Sep 2026 · entity.evidence · checked 2026-09-20T00:00:00Z · snapshot b7633f732437

  4. 0 interventional studies on ClinicalTrials.gov match the published query.

    Published ClinicalTrials.gov query

    0 / Not available in this release. interventional registry studies · NIH DSLD snapshot Sep 2026 · entity.registered_trials · checked 2026-09-20T00:00:00Z · snapshot b7633f732437

  5. 0 of 1 SKUs containing Limosilactobacillus reuteri ATCC PTA 6475 have a numeric price observation (0.0%) in the release accompanying the NIH DSLD snapshot Sep 2026.

    0 / 1 containing SKUs · NIH DSLD snapshot Sep 2026 · entity.price · checked 2026-09-20T00:00:00Z · snapshot b7633f732437

Back to the release hub